×
News Home

Where Does Immunitybio Inc (IBRX) Stock Fall in the Biotechnology Field After It Is Higher By 15.17% This Week?

Friday, August 05, 2022 01:51 PM | InvestorsObserver Analysts
Where Does Immunitybio Inc (IBRX) Stock Fall in the Biotechnology Field After It Is Higher By 15.17% This Week?

The 37 rating InvestorsObserver gives to Immunitybio Inc (IBRX) stock puts it near the bottom of the Biotechnology industry. In addition to scoring higher than 23 percent of stocks in the Biotechnology industry, IBRX’s 37 overall rating means the stock scores better than 37 percent of all stocks.

Overall Score - 37
IBRX has an Overall Score of 37. Find out what this means to you and get the rest of the rankings on IBRX!

What do These Ratings Mean?

Finding the best stocks can be tricky. It isn’t easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObserver’s tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.
Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObserver’s overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. There’s no need to try to remember what is “good” for a bunch of complicated ratios, just pay attention to which numbers are the highest.

What's Happening With Immunitybio Inc Stock Today?

Immunitybio Inc (IBRX) stock has gained 5.91% while the S&P 500 is lower by -0.27% as of 1:50 PM on Friday, Aug 5. IBRX has risen $0.25 from the previous closing price of $4.23 on volume of 824,515 shares. Over the past year the S&P 500 is lower by -6.51% while IBRX is lower by -60.56%. IBRX lost -$0.94 per share the over the last 12 months. Click Here to get the full Stock Report for Immunitybio Inc stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App